



Supplementary Fig. S5. Target downregulation of DGKA and cisplatin treatment does not alter metabolic features in ovarian cancer cells. A2780^{cisR} and SK-OV-3^{cisR} cells with or without DGKA knockdown were treated with sublethal doses of cisplatin (5 μ g/ml A2780^{cisR} and 2 μ g/ml SK-OV-3^{cisR}) for 12 hours (ROS) or 24 hours (lipid, RNA, and ATP). Lipid and RNA synthesis (A and B), intracellular ATP level (C), and ROS level (D) were measured by ¹⁴C-glucose labeling, ATP bioluminescent somatic cell assay, and CM-H₂DCFDA staining, respectively. n=3 technical replicates. Results of one representative experiment from two independent experiments are shown for all panels. Error bars represent SD. P values were determined by one-way ANOVA (ns: not significant).